Statement: The most frequent adverse event in cohort 1 of the primary trial was lymphopenia.
Primary_evidence: Adverse Events 1:   Total: 22/96 (22.92%)   Anemia 1/96 (1.04%)   lymphopenia 1/96 (1.04%)   cardiac ischemia/infarction 1/96 (1.04%)   sinus tachycardia 2/96 (2.08%)   Dehydration 5/96 (5.21%)   colitis 1/96 (1.04%)   diarrhea 5/96 (5.21%)   ileus 1/96 (1.04%)   nausea 2/96 (2.08%)   vomiting 1/96 (1.04%)   distal small bowel obstruction 1/96 (1.04%)   edema 1/96 (1.04%)   fatigue 2/96 (2.08%) Adverse Events 2:   Total: 6/49 (12.24%)   Anemia 0/49 (0.00%)   lymphopenia 0/49 (0.00%)   cardiac ischemia/infarction 0/49 (0.00%)   sinus tachycardia 0/49 (0.00%)   Dehydration 1/49 (2.04%)   colitis 0/49 (0.00%)   diarrhea 0/49 (0.00%)   ileus 0/49 (0.00%)   nausea 1/49 (2.04%)   vomiting 1/49 (2.04%)   distal small bowel obstruction 0/49 (0.00%)   edema 0/49 (0.00%)   fatigue 0/49 (0.00%)